Eli Lilly's higher guidance, Mounjaro data set the Club name up for a solid 2023

Eli Lilly (LLY) made up for a first-quarter earnings miss with a raised outlook and positive obesity-trial data for a potential blockbuster drug.

from US Top News and Analysis https://ift.tt/416LRAK
https://ift.tt/CzIcYnr